Is Capsule profitable in 2026?

Capsule does not publicly disclose revenue or profitability. A third-party review site noted as of May 2026 that the company has not released profitability figures, and no primary financial statements have surfaced since its 2021 Series D round.

Has Capsule done layoffs?

Yes. Capsule cut 13% of its workforce in July 2022, per Crain's New York, after PitchBook data put headcount at 938 in May 2022. Multiple workforce trackers show continued headcount decline into 2025 and 2026.

Who owns Capsule the pharmacy startup?

Capsule is privately held and venture-backed, with no parent company. Investors include Thrive Capital, TCV, Glade Brook Capital, Virgin Group, and Durable Capital Partners, which led its $300M Series D in April 2021.

What is Capsule's valuation right now?

Capsule's last confirmed valuation exceeded $1B, set during its $300M Series D led by Durable Capital Partners on April 28, 2021. No third-party press has confirmed a new priced round or valuation update since then, as of mid-2026.

Could AI replace Capsule's pharmacy service?

AI could commoditize Capsule's pharmacist chat, prior-authorization, and refill-reminder workflows, which CEO Eric Kinariwala described using AI for in a March 2026 podcast. However, Capsule's state pharmacy licenses, DEA registration, and physical delivery infrastructure resist pure AI substitution.

Who is Capsule's biggest competitor?

Amazon Pharmacy, built on its 2018 PillPack acquisition, operates in 45+ states as of September 2021, dwarfing Capsule's roughly 5-6 active metros in 2026. Alto Pharmacy is also cited as a better-funded structural peer.

United States · United States

Capsule

Capsule is a licensed delivery pharmacy operating in about 5-6 US metros.

Losing its protection

Assessed 29 July 2026 · Evidence as of 29 July 2026

The structural protection is eroding.

On the recordSince 29 July 2026 · Checkable from 2026 · Every call on the record Checkpoint: Verification of Crain's Feb 2026 'new capital raise' headline as real or re-published 2021 story

The call

Capsule still fills and delivers prescriptions, but five years without a confirmed new round and shrinking metro footprint show a company holding ground, not expanding it.

Capsule operates a licensed pharmacy that delivers medications to customers in a handful of cities, competing directly with Amazon Pharmacy (which already reaches 45+ states through its PillPack acquisition) and other well-funded startups like Alto. Amazon and rivals have more money, bigger reach, and the same basic business model, making it hard for Capsule to stand out or survive on its own. The company shrank from nearly 1,000 employees to 700-850 people across fewer cities over five years without raising new money, suggesting serious financial trouble. What matters most: whether Capsule actually raises new funding in early 2026 (reports are unclear), and whether Amazon expands fast delivery into Capsule's remaining cities in the next year or two.

Why

AI pressure: None apparent. No AI product targets pharmacy delivery directly; the pressure on Capsule comes from logistics scale, not AI. Could AI do the core job? Only partly.

Bigger players: Amazon Pharmacy (PillPack). Amazon Pharmacy already ships prescriptions in 45+ states with Prime-linked delivery, competing head-on in Capsule's remaining metros. Could a giant copy it? Yes, easily.

What protects it. Local pharmacy licensing, payer contracts, and same-day delivery relationships in its remaining metros give Capsule some short-term insulation.

What would change this call

Confirmation of whether the Feb 2026 Crain's 'capital raise' report is a new priced round or a re-publication of the 2021 story. Shows whether Capsule can still attract fresh investor capital or is stalled since 2021.
Amazon Pharmacy launching same-day delivery in NYC, Chicago, Boston, Minneapolis, or Austin within 12-24 months. Would show Amazon directly overtaking Capsule's remaining core markets.
Capsule's headcount falling further below the current 700-850 range in public filings or press. Would indicate continued retrenchment rather than stabilization or growth.

Key numbers

$300M Series D raised, valuation topped $1B (2021-04-28)
13% of workforce laid off (2022-07-21)
Headcount down to roughly 700-850 from ~940 peak (2026-05-25)

Named risks

No confirmed priced funding round since April 2021 Series D, raising cash runway concerns. Severity: high
Headcount decline from roughly 900-940 in 2021-22 to 700-850 by 2026 across multiple trackers. Severity: high
Amazon Pharmacy's 45-state scale threatens Capsule's urban-metro-only model. Severity: high
Lacks 503B compounding relationships amid ongoing GLP-1 drug supply constraints. Severity: medium
2025 federal PBM oversight and reimbursement pressure compressing digital-pharmacy margins sector-wide. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Amazon Pharmacy	losing to	45+ state coverage since 2021 via PillPack versus Capsule's roughly 5-6 metros in 2026
Alto Pharmacy	losing to	Vendor comparison claims Alto raised over $500M and covers more metros than Capsule as of March 2026
CVS Health and Walgreens	losing to	Dominant retail chains control most of the $335-500B US prescription market Capsule competes for
Truepill	contesting	B2B white-label pharmacy infrastructure claims ~95% US coverage, different model than Capsule's direct-to-consumer app

Questions people ask

Is Capsule profitable in 2026?: Capsule does not publicly disclose revenue or profitability. A third-party review site noted as of May 2026 that the company has not released profitability figures, and no primary financial statements have surfaced since its 2021 Series D round.
Has Capsule done layoffs?: Yes. Capsule cut 13% of its workforce in July 2022, per Crain's New York, after PitchBook data put headcount at 938 in May 2022. Multiple workforce trackers show continued headcount decline into 2025 and 2026.
Who owns Capsule the pharmacy startup?: Capsule is privately held and venture-backed, with no parent company. Investors include Thrive Capital, TCV, Glade Brook Capital, Virgin Group, and Durable Capital Partners, which led its $300M Series D in April 2021.
What is Capsule's valuation right now?: Capsule's last confirmed valuation exceeded $1B, set during its $300M Series D led by Durable Capital Partners on April 28, 2021. No third-party press has confirmed a new priced round or valuation update since then, as of mid-2026.
Could AI replace Capsule's pharmacy service?: AI could commoditize Capsule's pharmacist chat, prior-authorization, and refill-reminder workflows, which CEO Eric Kinariwala described using AI for in a March 2026 podcast. However, Capsule's state pharmacy licenses, DEA registration, and physical delivery infrastructure resist pure AI substitution.
Who is Capsule's biggest competitor?: Amazon Pharmacy, built on its 2018 PillPack acquisition, operates in 45+ states as of September 2021, dwarfing Capsule's roughly 5-6 active metros in 2026. Alto Pharmacy is also cited as a better-funded structural peer.

Timeline

2026-03-17CEO Kinariwala discusses AI workflow automation and drone delivery exploration on podcast
2026-02-13Crain's headline on 'new capital raise' surfaces, ambiguous re-publication of 2021 story
2023-02-13PitchBook logs unverified $100M later-stage VC deal, fields incomplete
2022-07-21Capsule lays off 13% of workforce per Crain's New York
2021-04-28Series D closes at $300M led by Durable Capital Partners, valuation tops $1B
2019-09Series C raises $200M led by TCV
2017Series A raises approximately $20M
2015Capsule founded in New York City by Eric Kinariwala and Sonia Patel

Revision history

29 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

American Airlines Group Wayfair Safe Superintelligence Inc.